News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Marinomed Biotechnologie GmbH Appoints Head of Development


10/27/2011 9:49:00 AM

Vienna, Austria, 27 October 2011- Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has appointed Dr. Angelika Bodenteich as the Company’s new Head of Development. Dr. Bodenteich has also received commercial power of attorney.

Dr. Bodenteich will be presenting on Marinomed’s behalf during a seminar on influenza at the BIO-Europe conference from 31st October-2nd November in Düsseldorf, Germany. The title of the presentation is “Austrian Influenza Pipeline”, which will take place on Monday, 31st October from 17:30-18:15.

Dr. Bodenteich joins Marinomed from onepharm Research & Development, where she held the position of Chief Medical Officer for the last two years and Head Development for one year prior to that. Her main responsibilities in these positions included designing and conducting clinical trials, building partnerships with research institutions and general business development activities. She also spent four years at Sanochemia Pharmazeutika AG as Head of Research & Development, where she was responsible for both pharmaceutical and business development. Dr. Bodenteich has more than 15 years of experience in the pharmaceutical industry; she is a trained pathologist who held positions in research and industry in Austria, Norway and in the USA.

Dr. Andreas Grassauer, CEO and co-founder of Marinomed, commented:

“We are delighted to welcome Angelika to the team - her scientific and professional expertise in the area of Research and Development as well as her experience in international collaborations and business development will certainly be a significant addition to Marinomed as we work to further develop our pipeline.”

Commenting on her own appointment, Dr. Bodenteich noted:

“I am truly excited to be joining Marinomed and I look forward to working with the team, developing new innovative therapies against viral respiratory infections and immunological conditions.”

About Marinomed Biotechnologie GmbH

Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative anti-viral respiratory technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray against common cold. The huge potential of the technology is reflected by Marinomed´s additional products concentrating on influenza and combination products. In addition, the Company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria. For further information please visit the website at www.marinomed.com

Contact:

Johanna Uhlmann

Business Development

Marinomed Biotechnologie GmbH

Tel: +43 (0)1 25077 4460

johanna.uhlmann@marinomed.com

Dr. Robert Mayer

Account Director- Munich

College Hill

Tel : +49 (0) 89 5238 8030

robert.mayer@collegehill.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES